Asia Pacific bioanalytical testing services market will grow by 11.2% annually with a total addressable market cap of $ 13,359.1 million over 2022-2031, driven by the rising demand for analytical testing of biologics and biosimilars amid COVID-19 pandemic, increasing preference for outsourcing analytical testing, growing R&D expenditure in the pharmaceutical and biopharmaceutical industries, and the rising adoption of the Quality by Design (QbD) approach.
Highlighted with 36 tables and 78 figures, this 136-page report “Asia Pacific Bioanalytical Testing Services Market 2021-2031 by Molecule Type (Small, Large), Application (Bioavailability and Bioequivalence, PK, PD, ADME), Test Type (Cell-based, Virology, SINA, MDOV, Biomarker), Workflow Process (Sample Preparation, Sample Analysis, Others), Therapeutic Area (Oncology, Neurology, Infectious Diseases, Gastroenterology, Cardiology), End User (Pharma and Biopharma Companies, CDMOs, CROs), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific bioanalytical testing services market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific bioanalytical testing services market in every aspect of the classification from perspectives of Molecule Type, Application, Test Type, Workflow Process, Therapeutic Area, End User, and Country.
Based on Molecule Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Small Molecules
• Large Molecules
o LC-MS Studies
o Immunoassays
o Other Large Molecule Tests
Based Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Bioavailability and Bioequivalence Studies
• Pharmacokinetics (PK)
• Pharmacodynamics (PD)
• Absorption, Distribution, Metabolism, Excretion (ADME)
• Other Applications
By Test Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Cell-based Assays
o Bacterial Cell-based Assays
o Viral Cell-based Assays
• Virology Testing
o In Vitro Virology Testing
o In Vivo Virology Testing
o Species-Specific Viral PCR Assays
• Serology, Immunogenicity, and Neutralizing Antibodies (SINA)
o Bacterial Serology, Immunogenicity, and Neutralizing Antibodies
o Viral Serology, Immunogenicity, and Neutralizing Antibodies
• Method Development Optimization and Validation (MDOV)
• Biomarker Testing
• Pharmacokinetic Testing
• Other Test Types
By Workflow Process, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Sample Preparation
o Protein Precipitation
o Liquid-liquid Extraction (LLE)
• Sample Analysis
o Hyphenated Technique
o Chromatographic Technique
o Electrophoresis
o Ligand Binding Assay
o Mass Spectrometry
o Nuclear Magnetic Resonance
• Other Workflow Processes
By Therapeutic Area, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Oncology
• Neurology
• Infectious Diseases
• Gastroenterology
• Cardiology
• Other Therapeutic Areas
By End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Pharma and Biopharma Companies
• Contract Development and Manufacturing Organizations (CDMOs)
• Contract Research Organizations (CROs)
Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Application, Workflow Process, and Therapeutic Area over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Charles River Laboratories International Inc.
Covance Inc.
Eurofins Scientific
ICON PLC
Intertek Group PLC
IQVIA Holdings, Inc.
Laboratory Corporation of America Holdings
Medpace Holdings, Inc.
Pace Analytical Services LLC.
Parexel International Corporation
PPD Inc.
SGS SA
Syneos Health, LLC
Toxikon Corporation
WuXi Apptech Co., Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
For Sample Report Visit Here: https://www.rightsightresearch.com/reports/asia-pacific-bioanalytical-testing-services-market/rsr-855e2b2